المؤلفون: Jazieh, Abdul-Rahman, Bounedjar, Adda, Abdel-Razeq, Hikmat, Koksoy, Elif Berna, Ansari, Jawaher, Tfayli, Arafat H., Tashkandi, Emad M., Jastaniah, Wasil A., Alorabi, Mohamed Osama, Darwish, Amira D., Rabea, Ahmed Magdy, Al Olayan, Ashwaq, Ibnshamsah, Fahad, Errihani, Hassan, AlKaiyat, Mohammad Omar, Hussain, Fazal, Alkattan, Khaled, Bruinooge, Suanna Steeby, Garrett-Mayer, Elizabeth, Tamim, Hani

المصدر: Journal of Immunotherapy & Precision Oncology; May2024, Vol. 7 Issue 2, p82-88, 7p

مصطلحات موضوعية: SARS-CoV-2, ONCOLOGY, HEALTH outcome assessment, CANCER patients, REGRESSION analysis

مستخلص: Introduction: Despite extensive studies of the impact of COVID-19 on patients with cancer, there is a dearth of information from the Middle East and North Africa (MENA) region. Our study aimed to report pertinent MENA COVID-19 and Cancer Registry (MCCR) findings on patient management and outcomes. Methods: MCCR was adapted from the American Society of Clinical Oncology COVID-19 Registry to collect data specifically from patients with cancer and SARS-CoV-2 infection from 12 centers in eight countries including Saudi Arabia, Jordan, Lebanon, Turkey, Egypt, Algeria, United Arab Emirates, and Morocco. The Registry included data on patients and disease characteristics, treatment, and patient outcomes. Logistic regression was used to assess associations with mortality. Results: Between November 29, 2020, and June 8, 2021, data were captured on 2008 patients diagnosed with COVID-19 from the beginning of the pandemic. Median age was 56 years (16–98), 56.4% were females, and 26% were current or ex-smokers. Breast cancer (28.5%) was the leading diagnosis and 50.5% had metastatic disease. Delays of planned treatment (.14 days) occurred in 80.3% for surgery, 48.8% for radiation therapy, and 32.9% for systemic therapy. Significant reduction in the delays of all three treatment modalities occurred after June 1, 2020. All-cause mortality rates at 30 and 90 days were 17.1% and 23.4%, respectively. All-cause mortality rates at 30 days did not change significantly after June 1, 2020; however, 90-day mortality increased from 33.4% to 42.9% before and after that date (p ¼ 0.015). Multivariable regression analysis showed the following predictors of higher 30- and 90-day mortality: age older than 70 years, having metastatic disease, disease progression, and being off chemotherapy. Conclusion: Patients with cancer in the MENA region experienced similar risks and outcome of COVID-19 as reported in other populations. Although there were fewer treatment delays after June 1, 2020, 90-day mortality increased, which may be attributed to other risk factors such as disease progression or new patients who presented with more advanced disease. [ABSTRACT FROM AUTHOR]

: Copyright of Journal of Immunotherapy & Precision Oncology is the property of Innovations Journals and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Shafik, Nevine F., Darwish, Amira D., Allam, Rasha Mahmoud, Elsayed, Ghada M.

المصدر: Clinical Lymphoma Myeloma and Leukemia ; volume 21, issue 10, page 676-685 ; ISSN 2152-2650

مصطلحات موضوعية: Cancer Research, Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.clml.2021.05.005Test
https://api.elsevier.com/content/article/PII:S2152265021001816?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2152265021001816?httpAccept=text/plainTest

المؤلفون: Gawdat, Rania M., El-Hoseiny, Shereen M., Darwish, Amira D., Sheir, Rania E., El-Nabwey, Waleed M.

المساهمون: No Funds

المصدر: Comparative Clinical Pathology ; volume 26, issue 3, page 505-512 ; ISSN 1618-5641 1618-565X

مصطلحات موضوعية: Pathology and Forensic Medicine, Anatomy

الإتاحة: https://doi.org/10.1007/s00580-017-2409-3Test

المؤلفون: Rady, Asmhan S., Badawy, Ragia H., El Gamal, Basma M., Darwish, Amira D., Abdel Aziz, Rania S., El Gammal, Mosaad, Goweda, Reda A.

المصدر: Clinical Laboratory; Mar2020, Vol. 66 Issue 3, p401-408, 8p

مستخلص: Background: Acute myeloid leukemia is a heterogeneous group of diseases characterized by the uncontrolled proliferation of hematopoietic stem cells (HSCs) and progenitor cells with a reduced capacity to differentiate into mature cells. CXC chemokine receptor (CXCR4) and its ligand stromal derived factor-1 (SDF-1/CXCL12) are important players involved in cross-talk between leukemia cells and the bone marrow (BM) microenvironment. The aim to study the association between the immuno-histochemical CXCR4 expression and the clinical outcome of AML in adult Egyptian patients. Methods: Fifty-eight patients suffering from AML were recruited for this study, with an age range from 18 to 60 years and presenting from January 2013 to March 2017. All patients were subjected to complete blood count, BM aspiration, immunophenotyping, BM trephine biopsy, immunohistochemical staining with CXCR4 McAb and cytogenetics when feasible. Results: CXCR4 was widely expressed (55.2%) among the studied patients. There was a significant relationship between CXCR4 and patients' outcomes. Fifteen (71.4%) patients who died were CXCR4 positive. The estimated mean time until death among CXCR4 negative cases was 37.6 ± 4.04 months which was longer than that of CXCR4 positive cases who had mean of 20.04 ± 4.9 months p = 0.016. The risk for death among CXCR4 positive cases was higher than CXCR4 negative cases with hazard ratio (HR) = 2.147 (p = 0.048). Conclusions: These results suggest that CXCR4 was expressed in a subset of AML patients and was associated with poor prognosis. CXCR4 expression appears to be an independent prognostic factor for survival in a heterogeneous group of AML patients. [ABSTRACT FROM AUTHOR]

: Copyright of Clinical Laboratory is the property of Clinical Laboratory Publications GmbH and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)